Valneva SE (VALN) Cash from Operations (2021 - 2026)
Valneva SE's (VALN) quarterly Cash from Operations came in at 365272.64 in Q1 2026, up 95.51% year-on-year from 186829.55 in Q1 2025, and up 98.71% quarter-over-quarter from 28372396.63 in Q4 2025.
Valneva SE (VALN) Cash from Operations (2021 - 2026) Analysis & Trends
Valneva SE has disclosed Cash from Operations across 6 years of filings, most recently posting 365272.64 for Q1 2026.
- Cash from Operations for Q1 2026 came in at 365272.64, up 95.51% year-over-year; the trailing twelve-month figure through Mar 2026 was 50362209.73 (changed 0.07% YoY), and the FY2025 annual result was 59006529.8, up 17.85% from the prior year.
- Cash from Operations came in at 365272.64 for Q1 2026 at Valneva SE, up from 28372396.63 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 71079696976.12 in Q3 2023 to a low of 71224011635.87 in Q2 2023.
- The 5-year median for Cash from Operations is 28372396.63 (2025), against an average of 36863032.15.
- Peak annual rise in Cash from Operations reached 79290.74% in 2023, while the deepest fall reached 91891.49% in 2023.
- Valneva SE's Cash from Operations stood at 57907199.96 in 2022, then retreated by 20.17% to 69587489.55 in 2023, then jumped by 112.24% to 8514568.15 in 2024, then slumped by 433.22% to 28372396.63 in 2025, then surged by 98.71% to 365272.64 in 2026.
- The last three Cash from Operations figures came in at 365272.64 (Q1 2026), 28372396.63 (Q4 2025), and 18644090.6 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | -365,272.64 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -365,272.64 |
| Mar 31, 2026 | -365,272.64 |
| Dec 31, 2025 | -28.37 Mn |
| Dec 31, 2025 | -28.37 Mn |
| Sep 30, 2025 | -18.64 Mn |
| Sep 30, 2025 | -18.64 Mn |
| Jun 30, 2025 | -2.98 Mn |
| Jun 30, 2025 | -2.98 Mn |
| Mar 31, 2025 | -8.14 Mn |
| Mar 31, 2025 | -8.14 Mn |
| Dec 31, 2024 | 8.51 Mn |
| Dec 31, 2024 | 8.51 Mn |
| Sep 30, 2024 | -11.02 Mn |
| Sep 30, 2024 | -11.02 Mn |
| Jun 30, 2024 | -39.68 Mn |
| Jun 30, 2024 | -39.68 Mn |
| Mar 31, 2024 | -30.75 Mn |
| Mar 31, 2024 | -30.75 Mn |
| Dec 31, 2023 | -69.59 Mn |
| Dec 31, 2023 | -69.59 Mn |